Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04666636 · ClinicalTrials.gov registry record · Phase 2
Mechanisms for Activation of Beige Adipose Tissue in Humans
A Phase 2 study of PreDiabetes, sponsored by Philip Kern.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT04666636: Recruiting Phase 2 study of PreDiabetes, sponsored by Philip Kern.
NCT04666636 is a Phase 2 study of PreDiabetes that is actively recruiting participants, run by Philip Kern. The registered enrollment target is 65 participants, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04666636, a Phase 2 study of PreDiabetes, is actively recruiting participants, sponsored by Philip Kern.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients
Primary Outcome
The standard oral glucose tolerance test (OGTT) using 75g glucose will be used to assess tolerance.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mirabegron 50 MG
- DRUG Mirabegron
- DRUG Mirabegron 100 mg
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2020-12-07 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 2 |
What NCT04666636 shows while recruiting
NCT04666636 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (91% lower).
The record links to 1 condition, with PreDiabetes appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT04666636 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT04666636 about?
NCT04666636 is a clinical study titled "Mechanisms for Activation of Beige Adipose Tissue in Humans". Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients
What is the current status of trial NCT04666636?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2020-12-07. Estimated completion is 2026-12-01.
What conditions does trial NCT04666636 study?
This clinical trial studies the following conditions: PreDiabetes.
What interventions are being tested in trial NCT04666636?
The interventions under investigation include: Placebo (DRUG), Mirabegron 50 MG (DRUG), Mirabegron (DRUG), Mirabegron 100 mg (DRUG).
Who is sponsoring clinical trial NCT04666636?
This trial is sponsored by Philip Kern, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04666636 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PreDiabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04666636's enrollment target sits among peer trials
65 86th of 149 higher than 63 of 149 other PreDiabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PreDiabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
RECRUITING · Phase 2
-
Social Determinants and a Diabetes Prevention Program Tailored for African Americans
RECRUITING · Phase 2
-
Long Term Impact of Time-Restricted Eating on Parameters of Cardiometabolic Health
RECRUITING · Phase 2
-
An Open-Label Pilot Intervention Trial to Prevent Diabetes in Prediabetic Adult Survivors of Childhood Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI